HoldsUp

Huberman Lab · 2025-11-24 · Andrew Huberman (host), Thaïs Aliabadi

Female Hormone Health, PCOS, Endometriosis, Fertility & Breast Cancer | Dr. Thaïs Aliabadi

100 research-tied claims examined: 2 contradicted 9 overstated 16 context 70 supported 3 unverified

16 Needs context
0:05:20Thaïs Aliabadineeds contextmoderate

PCOS and endometriosis diminish both ovarian egg count and egg quality.

"The issue is PCOS and endometriosis affect your egg count and your egg quality." (said at 0:05:20)

While both conditions impact ovarian function and oocyte competence, they affect 'egg count' in opposite directions. Endometriosis is consistently associated with reduced ovarian reserve (significantly lower antral follicle count [AFC] and anti-Müllerian hormone [AMH] levels) as well as compromised oocyte quality. In contrast, polycystic ovary syndrome (PCOS) is characterized by an increased egg/follicle count (elevated AFC and abnormally high AMH levels due to follicular arrest), even though the hyperandrogenic and inflammatory microenvironment can impair oocyte maturation and quality. Thus, stating that both conditions affect egg count is broadly true, but needs qualification: PCOS increases antral follicle count rather than depleting it, whereas endometriosis diminishes it.

0:15:35Thaïs Aliabadineeds contextmoderate

PCOS affects 15% of women in the United States and over 20% in Middle Eastern countries.

"Number one, it affects 15% of women in this country. If you go to Middle Eastern countries, that number can go north of 20%." (said at 0:15:35)

Prevalence estimates for polycystic ovary syndrome (PCOS) vary substantially depending on the diagnostic criteria applied (e.g., National Institutes of Health [NIH] criteria vs. Rotterdam criteria) and study design. Under the broader Rotterdam criteria, published estimates for reproductive-aged women in Western populations, including the US, often range from 10% to 15% (though coding-based or NIH-criteria estimates are lower, typically 5-10%). In the Middle East, meta-analytic data show significant regional variation: while pooled prevalence across the entire region is approximately 9% to 12%, prevalence in specific subregions such as Gulf Arab states has a pooled rate of 18.8% (95% CI: 9.5-30.3%) with individual study estimates ranging up to 27.6%. Thus, the numbers cited reflect high-end estimates and specific subregional cohorts using broader diagnostic definitions.

0:15:48Thaïs Aliabadineeds contextmoderate

Studies show that 70% of PCOS patients are never diagnosed.

"Studies show that 70% of these patients are never diagnosed." (said at 0:15:48)

Epidemiological studies and clinical guidelines (such as the international evidence-based PCOS guidelines) report that up to 70% of women meeting PCOS criteria remain undiagnosed at the time of screening. However, phrasing this as 70% being 'never diagnosed' conflates cross-sectional point underdiagnosis/diagnostic delay with lifetime non-diagnosis.

0:11:45Andrew Huberman (host)needs contextlow

Toxic PFAS (per- and polyfluoroalkyl substances) compounds are present in 80% of non-stick pans.

"Surprisingly, toxic compounds such as PFAS or forever chemicals are still found in 80% of non-stick pans, as well as utensils, appliances, and countless other kitchen products." (said at 0:11:45)

The claim refers to the prevalence of PTFE (polytetrafluoroethylene) coatings in non-stick cookware. PTFE is a fluoropolymer classified under the broad family of PFAS ('forever chemicals'). The specific ~80% figure stems from market testing (such as the 2020 Ecology Center study, which found 79% of non-stick pans tested were coated with PTFE). However, context is necessary: while PTFE is a persistent fluoropolymer in the PFAS class, manufacturing largely phased out older, highly toxic processing aids like PFOA (perfluorooctanoic acid) in favor of newer fluorinated compounds or alternative processes.

0:30:53Thaïs Aliabadineeds contextlow

In patients with PCOS who have regular menstrual cycles, bleeding is frequently caused by estrogen withdrawal rather than progesterone production following ovulation.

"Even these patients, a lot of times, are not ovulating. That regular cycle that you're seeing is estrogen withdrawal. It's not from the progesterone of ovulation." (said at 0:30:53)

While patients with PCOS can experience anovulatory menstrual bleeding resulting from estrogen withdrawal or estrogen breakthrough bleeding (due to fluctuating follicular development without corpus luteum formation and subsequent progesterone secretion), published literature indicates that the majority of PCOS patients with strictly regular menstrual cycles (eumenorrhea) are actually ovulatory, although a clinically meaningful minority (estimated between 15% to 40%) exhibit anovulatory cycles or luteal phase deficiency. Thus, asserting that regular cycles in PCOS are routinely or predominantly due to estrogen withdrawal rather than ovulatory progesterone withdrawal overgeneralizes anovulatory mechanisms to all regularly cycling patients.

0:39:43Thaïs Aliabadineeds contextlow

Of the 20 to 30 percent of PCOS patients who ovulate, approximately 40 percent fail to form a viable embryo or achieve pregnancy due to impaired egg quality and suboptimal endometrial progesterone receptivity.

"And 20 to 30% of them actually ovulate, right? But they don't always ovulate. That's the problem. And of the ones who ovulate, it gets worse. Of the ones who let's say, you know, this brain-pituitary-ovary axis is just partially disrupted, of the ones who ovulate, 40% of them, the embryo either doesn't form because the quality of the egg is bad, but also the environment is not ready for it, so the progesterone, the uterine lining is not ready for it." (said at 0:39:43)

While the biological mechanisms described—such as ovulatory dysfunction phenotypes in PCOS (~20–30% categorized as ovulatory PCOS / Phenotype C), diminished oocyte/egg quality, and impaired endometrial receptivity/progesterone resistance—are well-recognized in reproductive endocrinology, the specific figure that '40% of ovulating PCOS patients fail to form an embryo or achieve pregnancy specifically due to these dual factors' is a stylized clinical estimate rather than an established epidemiological statistic from published clinical trials.

0:55:57Thaïs Aliabadineeds contextmoderate

Each 0.1 ng/mL of anti-Müllerian hormone (AMH) corresponds on average to approximately one ovarian follicle.

"So AMH, anti-Müllerian hormone, the easiest way to look at it is every 0.1 of AMH averages to one follicle. That's an easy way to calculate it in your head, okay? So if you have an AMH of one, you should have about 10 follicles." (said at 0:55:57)

Serum anti-Müllerian hormone (AMH) and antral follicle count (AFC) are strongly correlated markers of ovarian reserve, and equating 0.1 ng/mL of AMH to approximately 1 follicle (i.e., an AMH of 1.0 ng/mL corresponding to ~10 follicles) is a common clinical rule of thumb. In standard reproductive medicine thresholds, an AMH cutoff of ~1.1 ng/mL aligns closely with an AFC threshold of 5–7 follicles, and normal-range AMH levels (1.0–3.0 ng/mL) broadly track total AFCs of 10–20. However, this is an informal mental heuristic rather than an exact biological equivalence: AMH is secreted by both pre-antral and small antral follicles, and clinical studies document discordance between AMH and AFC in approximately 20–30% of women due to inter-individual variation, age, polycystic ovarian morphology, and assay variability.

1:05:49Thaïs Aliabadineeds contexthigh

Metformin improves insulin sensitivity to clear glucose from the bloodstream into cells for energy.

"What does metformin do? Metformin basically makes us more insulin sensitive. It's opening these channels, so sugar clears the blood and goes into the cells where it turns into energy." (said at 1:05:49)

The speaker's description captures real secondary effects of metformin (improving insulin sensitivity and promoting peripheral glucose uptake/utilization into cells), but mischaracterizes its primary mechanism of action. The primary therapeutic effect of metformin in reducing blood glucose is the inhibition of hepatic glucose production (hepatic gluconeogenesis and glycogenolysis), along with actions in the gut, rather than primarily acting as an agent that 'opens channels' for peripheral glucose clearance.

1:05:56Thaïs Aliabadineeds contextmoderate

Approximately 80% of PCOS patients have insulin resistance.

"PCOS patients, especially the ones with insulin resistance, which is 80% of them" (said at 1:05:56)

Insulin resistance (IR) is a central metabolic feature of polycystic ovary syndrome (PCOS), widely reported in endocrine literature to affect approximately 60% to 80% of women with PCOS overall (reaching 75–95% in overweight/obese individuals and roughly 50–75% in lean individuals, depending on diagnostic criteria and measurement methods such as the hyperinsulinemic-euglycemic clamp vs. HOMA-IR). Stating a flat figure of 80% represents the upper end of prevalence estimates across unselected cohorts.

1:08:34Thaïs Aliabadineeds contextmoderate

Low vitamin D levels cause or worsen insulin resistance.

"Did you know that low vitamin D makes you insulin resistant?" (said at 1:08:34)

Extensive observational research, Mendelian randomization analyses, and meta-analyses of randomized controlled trials (RCTs) confirm a significant inverse association between vitamin D status and insulin resistance (measured by HOMA-IR). Meta-analyses of RCTs demonstrate that vitamin D supplementation improves insulin sensitivity and lowers HOMA-IR, particularly in individuals with baseline vitamin D deficiency or elevated BMI. However, phrasing this as a direct singular cause ('low vitamin D makes you insulin resistant') oversimplifies a multifactorial metabolic process where vitamin D is a contributing/modulating factor rather than an independent sole cause.

1:12:32Andrew Huberman (host)needs contexthigh

Berberine is derived from tree bark and functions as a glucose scavenger.

"You mentioned metformin several times. I'm aware of an over-the-counter version called berberine, which I believe comes from a tree bark, which is supposed to be a pretty potent glucose scavenger as well." (said at 1:12:32)

Berberine is a plant alkaloid extracted from the roots, rhizomes, and stem bark of various botanical species (such as Phellodendron amurense bark and Berberis species). Multiple clinical trials and systematic reviews demonstrate that berberine has glucose-lowering efficacy comparable to metformin in managing type 2 diabetes. However, describing it as a 'glucose scavenger' is a mechanistic misnomer: berberine does not directly bind, neutralize, or 'scavenge' circulating glucose molecules. Instead, it lowers blood glucose via intracellular signaling pathways, primarily by activating AMP-activated protein kinase (AMPK), enhancing insulin sensitivity, promoting GLUT4-mediated glucose uptake into tissues, and suppressing hepatic gluconeogenesis.

1:12:50Thaïs Aliabadineeds contextmoderate

Studies indicate that long-term use of berberine is not advised.

"So I think there are some studies that say long-term berberine is not advised." (said at 1:12:50)

The speaker claims that studies indicate long-term berberine use is not advised. Systematic reviews and randomized controlled trials show that clinical evaluations of berberine are almost exclusively limited to short-to-medium durations (typically 4 to 24 weeks or up to 3 months). Authoritative reviews caution against continuous long-term administration primarily due to the lack of long-term safety and efficacy data, potential drug interactions (via CYP450 enzyme inhibition), and gastrointestinal adverse effects, rather than direct evidence proving chronic toxicity in clinical trials.

1:19:54Thaïs Aliabadineeds contextmoderate

Among fertile couples having regular intercourse 3 to 4 times a week, 50% conceive within the first 6 months and 90% conceive within the first year.

"Because if you take um 100 couples regardless of age um and you have them have sex I don't know three to four times a week, 50% of them get pregnant in the first six months and 90% of them get pregnant in the first year." (said at 1:19:54)

The speaker's estimate for the 1-year cumulative conception rate (~90%) is consistent with standard reproductive literature, but the 6-month figure (50%) is an understatement for fertile couples having frequent intercourse. Prospective cohort studies (such as Gnoth et al., 2003) show that among couples attempting pregnancy with regular/timed intercourse, cumulative conception rates reach ~81% at 6 cycles (and ~88% in those who are ultimately fertile), reaching ~92% (and ~98%) by 12 cycles/1 year. Furthermore, the assertion that this occurs 'regardless of age' is inaccurate, as female fecundability declines with advancing age.

1:26:10Thaïs Aliabadineeds contextmoderate

Between 70% and 80% of PCOS patients do not ovulate (anovulatory).

"Understand that 70 to 80% of these patients don't ovulate. Understand that the 20–30% who ovulate ovulate sometimes, not all the time, and that's why they're not getting pregnant." (said at 1:26:10)

The speaker's statement that '70 to 80% of these patients don't ovulate' reflects a commonly cited clinical figure in reproductive endocrinology, but with an important distinction. In the literature, polycystic ovary syndrome (PCOS) is recognized as the cause of approximately 80% of all cases of anovulatory infertility. Under the standard Rotterdam diagnostic criteria (which require 2 out of 3 features: ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology), approximately 70% to 80% of women diagnosed with PCOS present with anovulatory or oligo-ovulatory phenotypes (Phenotypes A, B, and D), while roughly 20% to 30% have 'ovulatory PCOS' (Phenotype C). However, many women with PCOS experience oligo-ovulation (infrequent or irregular ovulation) rather than absolute, permanent anovulation.

1:37:15Thaïs Aliabadineeds contextlow

In the United States, it takes an average of 9 to 11 years and visits to 5 to 10 doctors for a patient to receive an endometriosis diagnosis.

"The problem with endometriosis is in this country, it takes doctors 9 to 11 years to diagnose endometriosis. On average, patients see 5 to 10 doctors, and that's not an exaggeration." (said at 1:37:15)

The speaker cites classical statistics frequently reported in endometriosis literature and patient registry data. Early US studies (e.g., Hadfield et al., 1996; Ballweg, 2004) reported an average delay between symptom onset and surgical diagnosis of 9 to 11.7 years, with patients seeing multiple physicians before receiving a definitive diagnosis. However, this delay represents total time from the onset of initial symptoms to diagnosis (combining patient delay in seeking care and healthcare system delay), rather than time spent under active physician investigation alone. Additionally, more recent US survey data (e.g., Soliman et al., 2017) suggest the average delay from symptom onset to diagnosis in the US has decreased to approximately 4.4 to 7 years.

2:01:20Thaïs Aliabadineeds contextmoderate

Laparoscopic surgical resection is the gold standard for diagnosing and treating endometriosis lesions compared to ablation or burning.

"The gold standard way of treating this is a laparoscopic resection of endometriosis. ... but surgery is the gold standard way of diagnosing a to be 100% if you're not confident and b cutting these excising these lesions. We used to burn them, but as of like for the past 15 years, we've learned that you really need to cut them. You don't want to burn them, right? Because burning them is just a band-aid and the pain comes back." (said at 2:01:20)

Laparoscopy with histological confirmation is widely recognized as the definitive diagnostic gold standard for endometriosis. Regarding treatment, the assertion that excision is clearly superior to ablation is accurate for ovarian endometriomas and deep infiltrating disease, where Cochrane systematic reviews confirm excision significantly reduces pain recurrence, lesion recurrence, and repeat surgery. However, for minimal-to-mild superficial peritoneal endometriosis, randomized controlled trials and meta-analyses show mixed results, with some finding modest benefits for excision and others finding no significant difference in pain relief between excision and ablation.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.